BioCentury
ARTICLE | Clinical News

Zybrestat fosbretabulin: Additional Phase II data

December 3, 2012 8:00 AM UTC

Additional data from the double-blind, Asian Phase II FAVOR trial in 20 patients with PCV showed that a single IV injection of 15 mg/kg Zybrestat led to a "transient" reduction in polyp activity as measured by ICGA in 1 patient. A single IV injection of 45 mg/kg Zybrestat led to a "transient" reduction in subretinal fluid seen on optical coherence tomography (OCT) in 1 patient. Furthermore, the proportion of eyes with worsened findings on OCT or ICGA was significantly lower in patients treated with Zybrestat vs. placebo (p=0.032). There were no treatment-related serious adverse events reported. Patients received a single IV injection of 15, 25, 35 or 45 mg/kg Zybrestat or placebo followed by imaging of the retina on days 2, 8, 15 and 28. OxiGene said it is seeking partners for its Zybrestat ophthalmology program. Data were presented at the American Academy of Ophthalmology meeting in Chicago. ...